BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 17935277)

  • 1. Cyclins and related kinases in cancer cells.
    Malumbres M
    J BUON; 2007 Sep; 12 Suppl 1():S45-52. PubMed ID: 17935277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development.
    Nakayama K; Nakayama K
    Bioessays; 1998 Dec; 20(12):1020-9. PubMed ID: 10048302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel potent pharmacological cyclin-dependent kinase inhibitors.
    Węsierska-Gądek J; Chamrád I; Kryštof V
    Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
    Fischer PM
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
    Ahn MY; Lee J; Na YJ; Choi WS; Lee BM; Kang KW; Kim HS
    Chem Biol Interact; 2009 May; 179(2-3):169-77. PubMed ID: 19070610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promises and drawbacks of targeting cell cycle kinases in cancer.
    Pentimalli F; Giordano A
    Discov Med; 2009 Dec; 8(43):177-80. PubMed ID: 20040266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whether to target single or multiple CDKs for therapy? That is the question.
    Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
    J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer--a review.
    Sarita Rajender P; Ramasree D; Bhargavi K; Vasavi M; Uma V
    J Recept Signal Transduct Res; 2010 Aug; 30(4):206-13. PubMed ID: 20560705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Ets transcription factor GABP is required for cell-cycle progression.
    Yang ZF; Mott S; Rosmarin AG
    Nat Cell Biol; 2007 Mar; 9(3):339-46. PubMed ID: 17277770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coming full circle: cyclin-dependent kinases as anti-cancer drug targets.
    Fisher RP
    Subcell Biochem; 2010; 50():1-15. PubMed ID: 20012574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA
    Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK activation by non-cyclin proteins.
    Nebreda AR
    Curr Opin Cell Biol; 2006 Apr; 18(2):192-8. PubMed ID: 16488127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclins and cdks in development and cancer: a perspective.
    Deshpande A; Sicinski P; Hinds PW
    Oncogene; 2005 Apr; 24(17):2909-15. PubMed ID: 15838524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the evaluation of CDK inhibitors as anti-tumor agents.
    McInnes C
    Drug Discov Today; 2008 Oct; 13(19-20):875-81. PubMed ID: 18639646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the cell cycle: a new approach to cancer therapy.
    Schwartz GK; Shah MA
    J Clin Oncol; 2005 Dec; 23(36):9408-21. PubMed ID: 16361640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential.
    Andrés V
    Cardiovasc Res; 2004 Jul; 63(1):11-21. PubMed ID: 15194457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cyclin-dependent kinases in apoptosis.
    Borgne A; Golsteyn RM
    Prog Cell Cycle Res; 2003; 5():453-9. PubMed ID: 14593740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.